新兴市场美元债-iShares EMB 深 沪
已收盘 10-10 16:00:00 美东时间
94.63
-0.420
-0.44%
华盛通- 最 高95.23
- 今 开95.14
- 成交量 1658.64万股
- 最 低 94.57
- 昨 收 95.05
- 总市值 136.27亿
- 52周最高 95.5075
- 市盈率 静 --
- 换手率 11.52%
- 52周最低 82.3869
- 委 比 -86.39%
- 总股本 1.44亿
- 历史最高 95.5075
- 量 比 2.43
- 振 幅 0.69%
- 历史最低 51.8899
- 每 手 1
- 风险率 2.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多T. ROWE PRICE GROUP REPORTS PRELIMINARY MONTH-END ASSETS UNDER MANAGEMENT FOR SEPTEMBER 2025
BALTIMORE, Oct. 10, 2025 /PRNewswire/ -- T. Rowe Price Group, Inc. (NASDAQ-GS: TROW) announced preliminary September month-end assets under management of $1.77 trillion. Preliminary net outf...
10-10 20:30
ChipMOS REPORTS 10.5% YoY INCREASE IN SEPTEMBER 2025 REVENUE; 3Q25 REVENUE INCREASES 7.1% QoQ
HSINCHU, Oct. 9, 2025/PRNewswire-FirstCall/ -- ChipMOS TECHNOLOGIES INC. ("ChipMOS" or the "Company") (Taiwan Stock Exchange: 8150 and Nasdaq: IMOS), an industry leading provider of outsourc...
10-09 18:00
IAC TO ANNOUNCE Q3 2025 EARNINGS ON NOVEMBER 3rd AND HOST EARNINGS CONFERENCE CALL ON NOVEMBER 4th
NEW YORK, Oct. 8, 2025 /PRNewswire/ -- After the close of market trading on Monday, November 3, 2025, IAC (NASDAQ: IAC) will post its third quarter results at https://ir.iac.com/quarterly-re...
10-09 04:10
Embelton Limited Updates Director’s Shareholding
The latest update is out from Embelton Limited ( ($AU:EMB) ). Embelton Limited ...
10-02 11:27
Globant unveils new $125 million share repurchase program
LUXEMBOURG, Oct. 1, 2025 /PRNewswire/ -- Yesterday, the board of directors of Globant S.A. (NYSE: GLOB) approved a new share repurchase program, authorizing the allocation of up to $50 milli...
10-02 04:25
FDA Approves Eli Lilly's Drug For Advanced Breast Cancer
Eli Lilly secured FDA approval for breast cancer drug Inluriyo and EU clearance for Alzheimer's therapy Kisunla following strong Phase 3 data.
09-26 21:12
Eli Lilly wins approval of imlunestrant for breast cancer
The U.S. FDA has approved Eli Lilly's (NYSE:LLY) imlunestrant, under the brand name Inluriyo, as a second-line therapy for ER+, HER2–, and ESR1-mutated advanced or metastatic breast cancer. The oral ...
09-26 03:21
U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor In the Phase 3 EMBER-3 trial, Inluriyo ...
09-26 02:01
Pembroke VCT PLC Secures Shareholder Approval at AGM
An update from Pembroke VCT ( ($GB:PEMB) ) is now available. Pembroke VCT PLC a...
09-26 00:47
万向钱潮：万向一二三已完成半固态电池安全突破
9月25日，万向钱潮（000559.SZ）在发布的投资者关系活动记录表中称，公司已将机器人业务确立为继轴承与汽车底盘系统之后的第三大战略业务板块，系统推进人形机...
09-25 16:38
公司简介
公司名称
|
iShares JP Morgan USD Emerging Markets Bond ETF
|
行业分类
|
Investment Trusts/Mutual Funds
|
业务描述
|
Exists as exchange Traded Fund
|
T. ROWE PRICE GROUP REPORTS PRELIMINARY MONTH-END ASSETS UNDER MANAGEMENT FOR SEPTEMBER 2025
BALTIMORE, Oct. 10, 2025 /PRNewswire/ -- T. Rowe Price Group, Inc. (NASDAQ-GS: TROW) announced preliminary September month-end assets under management of $1.77 trillion. Preliminary net outf...
10-10 20:30
ChipMOS REPORTS 10.5% YoY INCREASE IN SEPTEMBER 2025 REVENUE; 3Q25 REVENUE INCREASES 7.1% QoQ
HSINCHU, Oct. 9, 2025/PRNewswire-FirstCall/ -- ChipMOS TECHNOLOGIES INC. ("ChipMOS" or the "Company") (Taiwan Stock Exchange: 8150 and Nasdaq: IMOS), an industry leading provider of outsourc...
10-09 18:00
IAC TO ANNOUNCE Q3 2025 EARNINGS ON NOVEMBER 3rd AND HOST EARNINGS CONFERENCE CALL ON NOVEMBER 4th
NEW YORK, Oct. 8, 2025 /PRNewswire/ -- After the close of market trading on Monday, November 3, 2025, IAC (NASDAQ: IAC) will post its third quarter results at https://ir.iac.com/quarterly-re...
10-09 04:10
Embelton Limited Updates Director’s Shareholding
The latest update is out from Embelton Limited ( ($AU:EMB) ). Embelton Limited ...
10-02 11:27
Globant unveils new $125 million share repurchase program
LUXEMBOURG, Oct. 1, 2025 /PRNewswire/ -- Yesterday, the board of directors of Globant S.A. (NYSE: GLOB) approved a new share repurchase program, authorizing the allocation of up to $50 milli...
10-02 04:25
FDA Approves Eli Lilly's Drug For Advanced Breast Cancer
Eli Lilly secured FDA approval for breast cancer drug Inluriyo and EU clearance for Alzheimer's therapy Kisunla following strong Phase 3 data.
09-26 21:12
Eli Lilly wins approval of imlunestrant for breast cancer
The U.S. FDA has approved Eli Lilly's (NYSE:LLY) imlunestrant, under the brand name Inluriyo, as a second-line therapy for ER+, HER2–, and ESR1-mutated advanced or metastatic breast cancer. The oral ...
09-26 03:21
U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor In the Phase 3 EMBER-3 trial, Inluriyo ...
09-26 02:01
Pembroke VCT PLC Secures Shareholder Approval at AGM
An update from Pembroke VCT ( ($GB:PEMB) ) is now available. Pembroke VCT PLC a...
09-26 00:47
万向钱潮：万向一二三已完成半固态电池安全突破
9月25日，万向钱潮（000559.SZ）在发布的投资者关系活动记录表中称，公司已将机器人业务确立为继轴承与汽车底盘系统之后的第三大战略业务板块，系统推进人形机...
09-25 16:38
年度
|
派息内容
| 派息日期 |
0.39
|
2025-10-06
| |
0.40
|
2025-09-05
| |
0.41
|
2025-08-06
| |
0.38
|
2025-07-07
| |
0.41
|
2025-06-05
| |
0.40
|
2025-05-06
| |
0.40
|
2025-04-04
| |
0.39
|
2025-03-06
| |
0.44
|
2025-02-06
| |
0.25
|
2025-01-03
| |
0.43
|
2024-12-23
| |
0.39
|
2024-12-05
| |
0.42
|
2024-11-06
| |
0.39
|
2024-10-04
| |
0.37
|
2024-09-06
| |
0.39
|
2024-08-06
| |
0.38
|
2024-07-05
| |
0.36
|
2024-06-07
| |
0.36
|
2024-05-07
| |
0.37
|
2024-04-05
| |
0.39
|
2024-03-07
| |
0.37
|
2024-02-07
| |
0.36
|
2023-12-20
| |
0.33
|
2023-12-07
| |
0.36
|
2023-11-07
| |
0.35
|
2023-10-06
| |
0.36
|
2023-09-08
| |
0.35
|
2023-08-07
| |
0.35
|
2023-07-10
| |
0.35
|
2023-06-07
| |
0.35
|
2023-05-05
| |
0.36
|
2023-04-07
| |
0.38
|
2023-03-07
| |
0.31
|
2023-02-07
| |
0.34
|
2022-12-21
| |
0.34
|
2022-12-07
| |
0.38
|
2022-11-07
| |
0.37
|
2022-10-07
| |
0.31
|
2022-09-08
| |
0.35
|
2022-08-05
| |
0.36
|
2022-07-08
| |
0.33
|
2022-06-07
| |
0.36
|
2022-05-06
| |
0.38
|
2022-04-07
| |
0.36
|
2022-03-07
| |
0.37
|
2022-02-07
| |
0.37
|
2021-12-22
| |
0.36
|
2021-12-07
| |
0.36
|
2021-11-05
| |
0.35
|
2021-10-07
| |
0.35
|
2021-09-08
| |
0.35
|
2021-08-06
| |
0.36
|
2021-07-08
| |
0.36
|
2021-06-07
| |
0.35
|
2021-05-07
| |
0.35
|
2021-04-08
| |
0.35
|
2021-03-05
| |
0.36
|
2021-02-05
| |
0.40
|
2020-12-23
| |
0.40
|
2020-12-07
| |
0.40
|
2020-11-06
| |
0.37
|
2020-10-07
| |
0.33
|
2020-09-08
| |
0.33
|
2020-08-07
| |
0.33
|
2020-07-08
| |
0.34
|
2020-06-05
| |
0.38
|
2020-05-07
| |
0.41
|
2020-04-07
| |
0.42
|
2020-03-06
| |
0.41
|
2020-02-07
| |
0.44
|
2019-12-26
| |
0.41
|
2019-12-06
| |
0.41
|
2019-11-07
| |
0.40
|
2019-10-07
| |
0.41
|
2019-09-09
| |
0.42
|
2019-08-07
| |
0.44
|
2019-07-08
| |
0.46
|
2019-06-07
| |
0.45
|
2019-05-07
| |
0.45
|
2019-04-05
| |
0.44
|
2019-03-07
| |
0.44
|
2019-02-07
| |
1.29
|
2018-12-24
| |
0.45
|
2018-12-07
| |
0.46
|
2018-11-07
| |
0.45
|
2018-10-05
| |
0.44
|
2018-09-10
| |
0.44
|
2018-08-07
| |
0.45
|
2018-07-09
| |
0.45
|
2018-06-07
| |
0.41
|
2018-05-07
| |
0.37
|
2018-04-06
| |
0.34
|
2018-03-07
| |
0.31
|
2018-02-07
| |
0.37
|
2017-12-28
| |
0.45
|
2017-12-07
| |
0.45
|
2017-11-07
| |
0.45
|
2017-10-06
| |
0.45
|
2017-09-08
| |
0.45
|
2017-08-07
| |
0.44
|
2017-07-10
| |
0.44
|
2017-06-07
| |
0.44
|
2017-05-05
| |
0.44
|
2017-04-07
| |
0.44
|
2017-03-07
| |
0.44
|
2017-02-07
| |
0.26
|
2016-12-29
| |
0.45
|
2016-12-07
| |
0.45
|
2016-11-07
| |
0.50
|
2016-10-07
| |
0.49
|
2016-09-08
| |
0.50
|
2016-08-05
| |
0.53
|
2016-07-08
| |
0.44
|
2016-06-07
| |
0.41
|
2016-05-06
| |
0.43
|
2016-04-07
| |
0.44
|
2016-03-07
| |
0.42
|
2016-02-05
| |
0.55
|
2015-12-31
| |
0.43
|
2015-12-07
| |
0.44
|
2015-11-06
| |
0.47
|
2015-10-07
| |
0.46
|
2015-09-08
| |
0.42
|
2015-08-07
| |
0.42
|
2015-07-08
| |
0.42
|
2015-06-05
| |
0.40
|
2015-05-07
| |
0.38
|
2015-04-08
| |
0.36
|
2015-03-06
| |
0.38
|
2015-02-06
| |
0.60
|
2014-12-31
| |
0.42
|
2014-12-05
| |
0.40
|
2014-11-07
| |
0.39
|
2014-10-07
| |
0.29
|
2014-09-08
| |
0.40
|
2014-08-07
| |
0.40
|
2014-07-08
| |
0.41
|
2014-06-06
| |
0.42
|
2014-05-07
| |
0.43
|
2014-04-07
| |
0.43
|
2014-03-07
| |
0.42
|
2014-02-07
| |
0.42
|
2014-01-02
| |
0.41
|
2013-12-06
| |
0.44
|
2013-11-07
| |
0.43
|
2013-10-07
| |
0.46
|
2013-09-09
| |
0.45
|
2013-08-07
| |
0.44
|
2013-07-08
| |
0.41
|
2013-06-07
| |
0.41
|
2013-05-07
| |
0.41
|
2013-04-05
| |
0.43
|
2013-03-07
| |
0.43
|
2013-02-07
| |
0.39
|
2013-01-02
| |
0.39
|
2012-12-07
| |
0.41
|
2012-11-07
| |
0.40
|
2012-10-05
| |
0.43
|
2012-09-10
| |
0.45
|
2012-08-07
| |
0.45
|
2012-07-09
| |
0.44
|
2012-06-07
| |
0.44
|
2012-05-07
| |
0.45
|
2012-04-09
| |
0.45
|
2012-03-07
| |
0.43
|
2012-02-07
| |
0.41
|
2012-01-04
| |
0.44
|
2011-12-07
| |
0.44
|
2011-11-07
| |
0.44
|
2011-10-07
| |
0.44
|
2011-09-08
| |
0.42
|
2011-08-05
| |
0.45
|
2011-07-08
| |
0.46
|
2011-06-07
| |
0.45
|
2011-05-06
| |
0.45
|
2011-04-07
| |
0.45
|
2011-03-07
| |
0.45
|
2011-02-07
| |
0.46
|
2011-01-04
| |
0.46
|
2010-12-07
| |
0.44
|
2010-11-05
| |
0.45
|
2010-10-07
| |
0.44
|
2010-09-08
| |
0.43
|
2010-08-06
| |
0.46
|
2010-07-08
| |
0.45
|
2010-06-07
| |
0.47
|
2010-05-07
| |
0.48
|
2010-04-08
| |
0.49
|
2010-03-05
| |
0.48
|
2010-02-05
| |
0.42
|
2010-01-05
| |
0.42
|
2009-12-07
| |
0.45
|
2009-11-06
| |
0.45
|
2009-10-07
| |
0.49
|
2009-09-08
| |
0.45
|
2009-08-07
| |
0.47
|
2009-07-08
| |
0.49
|
2009-06-05
| |
0.58
|
2009-05-07
| |
0.52
|
2009-04-07
| |
0.49
|
2009-03-06
| |
0.49
|
2009-02-06
| |
0.36
|
2009-01-02
| |
0.51
|
2008-12-05
| |
0.45
|
2008-11-07
| |
0.44
|
2008-10-07
| |
0.45
|
2008-09-08
| |
0.43
|
2008-08-07
| |
0.38
|
2008-07-08
| |
0.46
|
2008-06-06
| |
0.45
|
2008-05-07
| |
0.46
|
2008-04-07
| |
0.42
|
2008-03-07
| |
0.48
|
2008-02-07
| |
0.16
|
2007-12-27
|
